vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $9.5M, roughly 1.4× ECB Bancorp, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 27.3%, a 48.4% gap on every dollar of revenue. ECB Bancorp, Inc. produced more free cash flow last quarter ($9.0M vs $-2.1M).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
ECBK vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $13.7M |
| Net Profit | $2.6M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | -86.5% |
| Net Margin | 27.3% | 75.7% |
| Revenue YoY | 33.8% | — |
| Net Profit YoY | 79.5% | 179.1% |
| EPS (diluted) | $0.32 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $13.7M | ||
| Q3 25 | $8.8M | $19.1M | ||
| Q2 25 | $8.0M | $8.1M | ||
| Q1 25 | $6.9M | $2.9M | ||
| Q4 24 | $7.1M | — | ||
| Q3 24 | $6.6M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $6.2M | — |
| Q4 25 | $2.6M | $10.4M | ||
| Q3 25 | $2.4M | $-16.3M | ||
| Q2 25 | $1.4M | $-15.8M | ||
| Q1 25 | $1.3M | $-13.3M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $791.0K | — | ||
| Q1 24 | $621.0K | — |
| Q4 25 | 36.7% | -86.5% | ||
| Q3 25 | 37.0% | -10.1% | ||
| Q2 25 | 23.9% | -177.7% | ||
| Q1 25 | 24.9% | -472.7% | ||
| Q4 24 | 27.3% | — | ||
| Q3 24 | 23.3% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 13.4% | — |
| Q4 25 | 27.3% | 75.7% | ||
| Q3 25 | 27.7% | -85.4% | ||
| Q2 25 | 18.0% | -196.0% | ||
| Q1 25 | 18.7% | -452.7% | ||
| Q4 24 | 20.3% | — | ||
| Q3 24 | 17.2% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | $0.32 | $-3.74 | ||
| Q3 25 | $0.29 | $-0.11 | ||
| Q2 25 | $0.17 | $-0.16 | ||
| Q1 25 | $0.16 | $-0.18 | ||
| Q4 24 | $0.18 | — | ||
| Q3 24 | $0.14 | — | ||
| Q2 24 | $0.09 | — | ||
| Q1 24 | $0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $35.3M |
| Total Assets | $1.6B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $137.5M | ||
| Q3 25 | $201.9M | $103.8M | ||
| Q2 25 | $191.0M | $121.6M | ||
| Q1 25 | $143.7M | $89.1M | ||
| Q4 24 | $309.4M | — | ||
| Q3 24 | $114.8M | — | ||
| Q2 24 | $108.7M | — | ||
| Q1 24 | $109.8M | — |
| Q4 25 | $171.9M | $35.3M | ||
| Q3 25 | $169.3M | $-8.1M | ||
| Q2 25 | $168.3M | $7.1M | ||
| Q1 25 | $168.6M | $10.7M | ||
| Q4 24 | $168.3M | — | ||
| Q3 24 | $166.0M | — | ||
| Q2 24 | $166.5M | — | ||
| Q1 24 | $165.8M | — |
| Q4 25 | $1.6B | $154.7M | ||
| Q3 25 | $1.6B | $133.7M | ||
| Q2 25 | $1.5B | $133.8M | ||
| Q1 25 | $1.5B | $103.7M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-2.0M |
| Free Cash FlowOCF − Capex | $9.0M | $-2.1M |
| FCF MarginFCF / Revenue | 94.7% | -15.3% |
| Capex IntensityCapex / Revenue | 2.2% | 0.7% |
| Cash ConversionOCF / Net Profit | 3.55× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-2.0M | ||
| Q3 25 | $4.0M | $-17.5M | ||
| Q2 25 | $1.9M | $-14.5M | ||
| Q1 25 | $-631.0K | $29.0M | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | $861.0K | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $-429.0K | — |
| Q4 25 | $9.0M | $-2.1M | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | $-14.9M | ||
| Q1 25 | $-649.0K | $29.0M | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $-449.0K | — |
| Q4 25 | 94.7% | -15.3% | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | -184.0% | ||
| Q1 25 | -9.4% | 988.3% | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.4% | — | ||
| Q1 24 | -7.2% | — |
| Q4 25 | 2.2% | 0.7% | ||
| Q3 25 | 0.8% | 0.0% | ||
| Q2 25 | 0.6% | 5.0% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 3.55× | -0.19× | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
